Opko Health, Inc. To Hold Conference Call To Discuss Six Month Data From Phase 2 hGH-CTP Trial
Published: Jun 20, 2014
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE: OPK), a multinational biopharmaceutical and diagnostics company that is developing a novel long-acting human growth hormone product (hGH-CTP) for the treatment of growth hormone deficiency (GHD), today announced it will hold a conference call and webcast on Tuesday, June 24, 2014 at 8:30 a.m. EDT (7:30 a.m. CDT).
Help employers find you! Check out all the jobs and post your resume.